Suzhou Novoprotein (China) Today
| 688137 Stock | 34.21 0.21 0.62% |
PerformanceVery Weak
| Odds Of DistressQuite High
|
Suzhou Novoprotein is trading at 34.21 as of the 26th of February 2025, a 0.62% up since the beginning of the trading day. The stock's open price was 34.0. Suzhou Novoprotein has more than 67 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 28th of November 2024 and ending today, the 26th of February 2025. Click here to learn more.
Moving together with Suzhou Stock
Moving against Suzhou Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Suzhou Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Suzhou Novoprotein's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Suzhou Novoprotein or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Chairman Founder | Huaxing Zhu |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care (View all Sectors) |
Suzhou Novoprotein Scientific (688137) is traded on Shanghai Stock Exchange in China and employs 579 people. Suzhou Novoprotein is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.4 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Suzhou Novoprotein's market, we take the total number of its shares issued and multiply it by Suzhou Novoprotein's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Suzhou Novoprotein operates under Biotechnology sector and is part of Health Care industry. The entity has 70.18 M outstanding shares.
Suzhou Novoprotein generates positive cash flow from operations, but has no cash available
Check Suzhou Novoprotein Probability Of Bankruptcy
Ownership AllocationSuzhou Novoprotein shows a total of 70.18 Million outstanding shares. Suzhou Novoprotein has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 71.27 % of Suzhou Novoprotein outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Suzhou Ownership Details
Suzhou Novoprotein Risk Profiles
Although Suzhou Novoprotein's alpha and beta are two of the key measurements used to evaluate Suzhou Novoprotein's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 1.19 | |||
| Standard Deviation | 1.55 | |||
| Variance | 2.39 | |||
| Risk Adjusted Performance | (0.02) |
Suzhou Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Suzhou Novoprotein without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Manager Now
Portfolio ManagerState of the art Portfolio Manager to monitor and improve performance of your invested capital |
| All Next | Launch Module |
Suzhou Novoprotein Corporate Executives
Elected by the shareholders, the Suzhou Novoprotein's board of directors comprises two types of representatives: Suzhou Novoprotein inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Suzhou. The board's role is to monitor Suzhou Novoprotein's management team and ensure that shareholders' interests are well served. Suzhou Novoprotein's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Suzhou Novoprotein's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dongye Zhang | Accounting CFO | Profile |
Other Information on Investing in Suzhou Stock
Suzhou Novoprotein financial ratios help investors to determine whether Suzhou Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Suzhou with respect to the benefits of owning Suzhou Novoprotein security.